土井 洋平

Medicine & Life Sciences

1. Carbapenems 100%
2. Klebsiella pneumoniae 91%
3. Acinetobacter baumannii 66%
4. Colistin 57%
5. Escherichia coli 54%
6. Plasmids 47%
7. carbapenemase 47%
8. Carbapenem-Resistant Enterobacteriaceae 40%
9. Infections 35%
10. Aminoglycosides 30%
11. Genes 28%
12. Fosfomycin 27%
13. Enterobacteriaceae 25%
14. 16S Ribosomal RNA 24%
15. rRNA (adenosine-O-2'-)methyltransferase 23%
16. Pseudomonas aeruginosa 22%
17. Anti-Bacterial Agents 21%
18. Japan 21%
19. ceftazidime drug combination avibactam 19%
20. cefiderocol 18%
21. Molecular Epidemiology 18%
22. beta-lactamase CTX-2 17%
23. Bacteremia 16%
24. Cephalosporins 15%
25. Enterobacter cloacae 15%
26. Enterobacteriaceae Infections 15%
27. favipiravir 15%
28. Ertapenem 14%
29. Ceftazidime 14%
30. Bacteria 14%
31. Acinetobacter Infections 13%
32. Whole Genome Sequencing 13%
33. Gram-Negative Bacteria 13%
34. Lactams 13%
35. China 12%
36. Polymyxins 12%
37. Cefepime 11%
38. Epidemiology 11%
39. Methyltransferases 11%
40. Enterobacter 11%
41. Therapeutics 11%
42. Disease Outbreaks 11%
43. Mortality 10%
44. galantide 10%
45. Pulsed Field Gel Electrophoresis 10%
46. Tigecycline 9%
47. Serratia marcescens 9%
48. Cohort Studies 9%
49. Amikacin 9%
50. Multiple Drug Resistance 9%